Showing results (2081-2090 of 2,168) with videos related to

Sort By:
Pageof 217
Blood|August 4, 2012
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemiaAndres Jerez, Michael J Clemente, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2006
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer, David G Pfister, Scott A Laurie, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
International Journal of Molecular Sciences|February 25, 2023
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic SyndromesGrace A Ward, Robert P Dalton, Benjamin S Meyer, et al.
Frontiers in Oncology|July 22, 2022
Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivoReetobrata Basu, Yanrong Qian, Samuel Mathes, et al.
Lancet (London, England)|March 4, 2017
Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care settingCaterina Breitenstein, Tanja Grewe, Agnes Flöel, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2013
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patientsGisela Caceres, Kathy McGraw, Bon Ham Yip, et al.
Pageof 217